Artiva Biotherapeutics, Inc. Stock: price and insider trades · United States

Artiva Biotherapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 12 insiders published 61 filings.

On the market, 2 insiders bought (21 purchases totalling €18.5M) while 4 insiders sold (13 sales totalling €1.8M). The totals exclude 8 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €10.6M by GC Corp., published on 28 May 2026. Among those who bought: 1 major shareholder and 1 senior executive.

With 61 filings in twelve months, the company is more active than the median of 19 filings across the 5,808 companies we follow on the same exchange. Since 2024, the database holds 21 purchases and 14 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -83.9 m USD.

The clock since the last published purchase (31 July 2026) now reads 79 days. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade.

For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.